Clinical trial
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
NCT00043407 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00043407 |
|---|---|
| Title | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer |
| Official title | A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage Iv Renal Cell Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | CPG 7909 |
| Enrollment | 42 |
| Start date | Mar 1, 2002 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Aug 12, 2002 |
| Last update posted | Feb 12, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: